CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Medicine, Inc. (NASDAQ:FMI) today announced the launch of its
precision medicine partner program, Precision Medicine Exchange
Consortium™ (PMEC), to facilitate data exchange, advance research, and
support education and applications of precision medicine in oncology and
molecular pathology. PMEC brings together oncology thought leaders from
academic medical centers, regional hospital systems, and community oncology
networks, initially located in the U.S. and to be expanded
internationally, who share a vision for utilizing precision medicine as
a means for improving clinical outcomes in oncology treatment. The
consortium intends to realize this vision through a collaborative
exchange of molecular information and clinical outcomes data, and
through a broader integration of comprehensive genomic profiling in
Founding members of PMEC include The Cleveland Clinic's Taussig Cancer
Institute, Hackensack University Medical Center, The Robert H. Lurie
Comprehensive Cancer Center of Northwestern University, Sidney Kimmel
Cancer Center at Thomas Jefferson University, UC Davis Health
Comprehensive Cancer Center, the University of North Carolina Lineberger
Comprehensive Cancer Center, and Vanderbilt-Ingram Cancer Center and The
Wake Forest Baptist Comprehensive Cancer Center.
"Progress in cancer care will be achieved by breaking down the
information silos that exist in healthcare and collaborating towards
clinically robust and relevant data exchange," said Brian Bolwell, MD,
chairman of the Cleveland Clinic Cancer Institute and founding member of
PMEC. "We applaud Foundation Medicine and our partner institutions in
PMEC for their innovative thinking, for valuing the exchange of
information, and for taking a leadership role to effect a positive
change for our patients with cancer."
PMEC is being established on the guiding principles of innovation,
education and the exchange of highly validated molecular information and
outcomes data to improve cancer care. PMEC members will have access to a
suite of innovative information tools and programs tailored to fit the
needs of the individual cancer centers who are members of PMEC.
A selection of these planned offerings include:
access to a shared data exchange platform of de-identified, matched
clinical outcomes and genomic data contributed by Foundation Medicine
and PMEC members to support research and clinical innovation;
access to clinical research programs that integrate comprehensive
genomic profiling to improve cancer care; and
programs to support the advancement of precision medicine and
molecular oncology through training, education and streamlined member
Additionally, PMEC members can elect to participate in best practices
exchanges, where members will have the opportunity to share ideas
advancing precision medicine.
"The promise of precision medicine rests on these national and
international initiatives, including PMEC, which enable investigators to
share crucial data. Only through that data sharing can we understand the
implications of genomics for patient care," said Mary Zutter, M.D.,
assistant vice chancellor for Integrative Diagnostics at Vanderbilt
University Medical Center.
"The Precision Medicine Exchange Consortium is being developed as the
most comprehensive program of its kind and will align innovators in
cancer care around molecular information and clinical data curation and
exchange," said Vincent A. Miller, M.D., chief medical officer at
Foundation Medicine. "Collectively, PMEC is poised to fuel innovation,
support cancer research and extend valuable information and education in
a way that heretofore has not happened within the cancer community.
We're proud to be launching this initiative with so many thought leaders
across a broad spectrum of cancer institutions and practices. We're
actively seeking new members who share PMEC's vision, and we welcome
conversations with additional cancer centers, data and informatics
organizations and payers who embrace the opportunity to collaborate for
the betterment of cancer care."
About Foundation Medicine
Foundation Medicine (NASDAQ:FMI) is a molecular information company
dedicated to a transformation in cancer care in which treatment is
informed by a deep understanding of the genomic changes that contribute
to each patient's unique cancer. The company's clinical assays,
FoundationOne® for solid tumors and FoundationOne® Heme for hematologic
malignancies and sarcomas, provide a comprehensive genomic profile to
identify the molecular alterations in a patient's cancer and match them
with relevant targeted therapies and clinical trials. Foundation
Medicine's molecular information platform aims to improve day-to-day
care for patients by serving the needs of clinicians, academic
researchers and drug developers to help advance the science of molecular
medicine in cancer. For more information, please visit http://www.FoundationMedicine.com
or follow Foundation Medicine on Twitter (@FoundationATCG).
Foundation Medicine® is a registered trademark, and Precision
Medicine Exchange Consortium™, PMEC CORE™, PMEC Research™, and PMEC
Education™ are trademarks, of Foundation Medicine, Inc.
Cautionary Note Regarding Forward-Looking Statements
This press release contains "forward-looking statements" within the
meaning of the Private Securities Litigation Reform Act of 1995,
including, but not limited to, statements regarding the vision,
objectives, members and offerings of Precision Medicine Exchange
Consortium, the initiation of PMEC programs, and the ability of PMEC to
affect cancer research and cancer care. All such forward-looking
statements are based on management's current expectations of future
events and are subject to a number of risks and uncertainties that could
cause actual results to differ materially and adversely from those set
forth in or implied by such forward-looking statements. These risks and
uncertainties include the risks that PMEC is unable to successfully
combine and share de-identified clinical outcomes and genomic
information, to provide patients of PMEC members with access to clinical
trials; and the risks described under the caption "Risk Factors"
in Foundation Medicine's Quarterly Report on Form 10-Q for the three
months ended March 31, 2015, which is on file with the Securities and
Exchange Commission, as well as other risks detailed in subsequent
filings with the Securities and Exchange Commission, may be realized.
All information in this press release is as of the date of the release,
and Foundation Medicine undertakes no duty to update this information
unless required by law.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150915005991/en/
Pure Communications, Inc.
Susan Hager, 617-418-2258
Source: Foundation Medicine
News Provided by Acquire Media